Press Releases

Date	Title	Company
23-Feb-2022	Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall survival in patients with metastatic hormone-sensitive prostate cancer	Orion Corporation
23-Feb-2022	Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program	Sanofi
23-Feb-2022	Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Presented at ASCO-GU	Orion Corporation
23-Feb-2022	Completion of sale of Gyroscope Therapeutics	Syncona Ltd
23-Feb-2022	Almirall launches innovative Wynzora® CAL/BDP cream in Europe for the treatment of mild to moderate plaque psoriasis in adults including scalp	Almirall
23-Feb-2022	Immutep to present new data from the phase II TACTI-002 study of efti at ESMO’s European Lung Cancer Congress 2022	Immutep Limited
23-Feb-2022	Dante Labs Partnering with The Renato Dulbecco Foundation to advance personalized medicines for cancer, COVID-19 and rare diseases	Dante Labs
23-Feb-2022	High infliximab trough levels are associated with low risk of relapse when switching to subcutaneous infliximab in patients with inflammatory bowel disease, suggests new data presented at ECCO 2022 virtual congress	Celltrion Healthcare
23-Feb-2022	MODERNA EXPANDS ITS MRNA PIPELINE WITH THREE NEW DEVELOPMENT PROGRAMS	MODERNA
23-Feb-2022	Dr. Jorge Gallardo Ballart announces his intention to retire from his positions of President of the Board of Directors and Board member of Almirall	Almirall, S.A. (ALM)
23-Feb-2022	Half-Year Results for the Six Months Ended 31 December 2021 and Notice of Investor Presentation	Sareum Holdings plc
23-Feb-2022	NHS gene testing does not detect half of people at cancer risk	The Institute of Cancer Research, London
23-Feb-2022	US$100M VC Fund True Global Ventures injects US$8.3 million funding to US-based Chronicled to automate Healthcare Industry	True Global Ventures 4 Plus
23-Feb-2022	4D pharma announces FDA clearance of IND application for Live Biotherapeutics MRx0005 and MRx0029 for the treatment of Parkinson’s disease	4D pharma
23-Feb-2022	Oxurion NV announces 2021 Full Year Results and 2022 Outlook	Oxurion NV
23-Feb-2022	TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients	TargED Biopharmaceuticals
23-Feb-2022	Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2021 Results Presentation and Webcast	Nordic Nanovector ASA
23-Feb-2022	AstraZeneca progresses Ambition Zero Carbon programme with Honeywell partnership to develop next-generation respiratory inhalers	AstraZeneca
23-Feb-2022	Gendius initiates GP data study to develop enhanced risk prediction tools for diabetes	Gendius
23-Feb-2022	CSL Behring joins the ABPI	CSL Behring